HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

GRDN

Guardian Pharmacy Services, Inc. (NYSE)

Healthcare — Medical Care Facilities

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.

Strong Buy 1.2 / 5 6 analysts
$42.13
+$0.26 (+0.62%)
Target: $47.00 (11.6%)
Sign in to add GRDN to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$2.67B
P/E Ratio (TTM)50.15
Forward P/E31.02
EPS (TTM)$0.84
Dividend Yield-
Profit Margin3.65%
Revenue Growth2.20%
ROE26.91%
Debt/Equity17.72
Recommendation Strong Buy 1.2
Analyst Target$47.00
Analysts6
Indexes NYSE

Technical Indicators

RSI (14)50.5
Beta-
SMA 20-
SMA 40-
52-Week High$44.00
52-Week Low$19.30
50-Day Avg$38.87
200-Day Avg$32.82
Avg Volume438.8K
Volume451.7K

Performance Analysis

NEUTRAL

GRDN presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($44.00), which may indicate limited upside.
~ RSI at 50.5 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 50.2 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 2.2% year-over-year.
+ Wall Street consensus is "Strong Buy" from 6 analysts.
+ Average analyst target of $47.00 implies 11.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:12 UTC

Back to Screener Export Report